Choong Ang Vaccine Laboratory

As of March 31, 2026, Choong Ang Vaccine Laboratory carries a market capitalization of 83.31B, placing it among publicly traded companies globally. Its enterprise value stands at 65.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Choong Ang Vaccine Laboratory has 9.26M shares outstanding.

As of March 31, 2026, Choong Ang Vaccine Laboratory trades at a trailing price-to-earnings ratio of 11.38. The price-to-sales ratio is 1.73, and the price-to-book ratio stands at 0.78.

As of March 31, 2026, Choong Ang Vaccine Laboratory trades at an EV/EBITDA multiple of 4.76 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 9.09 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Choong Ang Vaccine Laboratory trades at an EV/FCF ratio of 12.31, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 65.33B versus a market cap of 83.31B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Choong Ang Vaccine Laboratory maintains a current ratio of 4.38, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.97, indicating elevated leverage, while an interest coverage ratio of 66.91 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Choong Ang Vaccine Laboratory posted a return on equity (ROE) of 7.05, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.19 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.96, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.78, useful for judging operating efficiency across full business cycles. The company generates approximately 254.18M in revenue per employee across its workforce of 190.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.20 indicates how many times Choong Ang Vaccine Laboratory sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Choong Ang Vaccine Laboratory recorded 270.32M in income tax expense. That works out to an effective tax rate of 3.54, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 7.65B, leaving 7.38B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Choong Ang Vaccine Laboratory's stock has declined approximately 6.12% over the past 52 weeks. The 50-day moving average sits at 9,184.60, while the 200-day moving average is 9,398.25.

Over the twelve months ended March 31, 2026, Choong Ang Vaccine Laboratory generated 48.42B in revenue and converted that into 7.38B in net income, yielding earnings per share of 790.93. EBITDA reached 13.73B, while operating income came in at 7.19B.

As of March 31, 2026, Choong Ang Vaccine Laboratory holds 24.36B in cash and equivalents against 6.38B in total debt, resulting in a net debt position of -6.17B. Total book value stands at 106.81B, with working capital of 41.38B providing operational flexibility.

Choong Ang Vaccine Laboratory produced 11.16B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -6.05B in capital expenditures, free cash flow totaled 5.11B - equivalent to 548.13 per share.

Over the twelve months ended March 31, 2026, Choong Ang Vaccine Laboratory posted a gross margin of 49.02, reflecting its pricing power and cost economics. The operating margin of 14.85 and net profit margin of 15.23 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Choong Ang Vaccine Laboratory paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 6.09, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.95, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Choong Ang Vaccine Laboratory shareholders.

Choong Ang Vaccine Laboratory's most recent stock split took place on July 18, 2018 with a 5:6 split ratio.

As of March 31, 2026, Choong Ang Vaccine Laboratory has an Altman Z-Score of 4.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.